Ghassan Abou Alfa

New York

@MSKCancerCenter Medical Oncologist, liver, cholangiocarcinoma, gallbladder, biliary cancer specialist. Global healthcare specialist. Patients’ advocate.

Featured in: Favicon

nih.gov

wiley.com

jamanetwork.com Favicon

medscape.com Favicon

thelancet.com Favicon

healio.com Favicon

amegroups.com Favicon

futuremedicine.com Favicon

onclive.com Favicon

curetoday.com + 8 more

Articles

HIMALAYA Overall Survival Prominence and Other Routes to the Peak

Jan 11, 2024 | jamanetwork.com | Ghassan Abou Alfa |Bruno Sangro |Sarah Cappuyns

HIMALAYA Overall Survival Prominence and Other Routes to the Peak Critical Appraisal of Recommendations on Systemic Therapies for Advanced HCC Sarah Cappuyns, MD; Virginia Corbett, MD; Mark Yarchoan, MD; Richard S. Finn, MD; Josep M. Llovet, MD, PhD HIMALAYA Overall Survival Prominence and Other Routes to the Peak—Reply Josep M. Llovet, MD, PhD; Sarah Cappuyns, MD, PhD; Richard S.
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

Sep 6, 2023 | futuremedicine.com | Ghassan Abou Alfa |George Lau |Masatoshi Kudo |Stephen Chan

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereFinancial & competing interests disclosureThis study was sponsored by AstraZeneca. We thank the participants in this study and their families, all the investigators and study site personnel, and the members of the independent data monitoring committee.
Optimal Sequencing in Patients With Advanced HCC

Aug 3, 2023 | onclive.com | Rachna T Shroff |Manish Shah |Julio Gutiérrez |Ghassan Abou Alfa

Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.
Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study

Aug 3, 2023 | onclive.com | Rachna T Shroff |Manish Shah |Julio Gutiérrez |Ghassan Abou Alfa

Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.
Phase 3 RATIONALE-301 Study Evaluates Tislelizumab vs Sorafenib in HCC

Jul 28, 2023 | targetedonc.com | Ghassan Abou Alfa

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the phase 3 RATIONALE-301 trial (NCT03412773) which evaluated frontline tislelizumab vs sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC). In the RATIONALE-301 trial, tislelizumab demonstrated improved health-related quality of life, physical functioning, fatigue, and HCC symptom index when compared with sorafenib. However, the agent did not reduce pain significantly vs sorafenib.
Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

Jul 28, 2023 | onclive.com | Rachna T Shroff |Manish Shah |Julio Gutiérrez |Ghassan Abou Alfa

Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.
The Role of Adjuvant Therapy in Patients With Early-Stage HCC

Jul 28, 2023 | onclive.com | Rachna T Shroff |Manish Shah |Julio Gutiérrez |Ghassan Abou Alfa

The Role of Adjuvant Therapy in Patients With Early-Stage HCCExperts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.
Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC

Jul 19, 2023 | onclive.com | Rachna T Shroff |Manish Shah |Julio Gutiérrez |Ghassan Abou Alfa

Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCCThe panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.
Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data - npj Precision Oncology

Mar 23, 2023 | nature.com | Travis Zack |Atul J. Butte |Ghassan Abou Alfa |Kurt P. Losert

AbstractThe incidence and biochemical consequences of rare tumor subtypes are often hard to study. Fibrolamellar liver cancer (FLC) is a rare malignancy affecting adolescents and young adults. To better characterize the incidence and biochemical consequences of this disease, we combined a comprehensive analysis of the electronic medical record and national payer data and found that FLC incidence is likely five to eight times higher than previous estimates.
Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma

Mar 21, 2023 | acsjournals.onlinelibrary.wiley.com | Ghassan Abou Alfa |Xiaoliang Wang |Christina M. Parrinello |Anala Gossai

Abstract Background Clinical trials suggest α-fetoprotein (AFP) reduction may be prognostic among patients with advanced hepatocellular carcinoma. However, the association of AFP reduction with outcomes in real-world settings is unclear. Methods Patients with advanced hepatocellular carcinoma between January 1, 2011, and June 30, 2021, first-line tyrosine kinase inhibitor, and baseline and posttreatment AFP values (closest to 8 ± 2 weeks after first-line initiation) were included.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers: 5K
Tweets: 2K
DMs Open: No

Ghassan Abou-Alfa @GABOUALFA

17 Apr 25

RT @OncBrothers: Working on Her2 discussions. A few things to keep in🧠: HER2 definition/approvals/response rates differ. - Overexpression:…

Ghassan Abou-Alfa @GABOUALFA

18 Mar 25

RT @sitcancer: Join us April 23, for a live virtual expert-led cancer IO program, ACI: A Focus on Gastrointestinal Cancers. Discuss ongoing…

Ghassan Abou-Alfa @GABOUALFA

6 Mar 25

Congratulations @MSKCancerCenter @MSK_RadOnc Christopher Crane! Thanks @NatPancFdn! https://t.co/oo7vnU7zSB

Ghassan Abou Alfa

Articles

HIMALAYA Overall Survival Prominence and Other Routes to the Peak

Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

Optimal Sequencing in Patients With Advanced HCC

Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study

Phase 3 RATIONALE-301 Study Evaluates Tislelizumab vs Sorafenib in HCC

Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

The Role of Adjuvant Therapy in Patients With Early-Stage HCC

Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC

Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data - npj Precision Oncology

Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma

Contact details

Emails

Socials & Sites

X (formerly Twitter)